A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer (NCT05678010)

🧪 Interventions in This Study

• AZD1390 (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Willing and able to provide written informed consent
2. Aged at least 18 years.
3. Karnofsky Performance Score (KPS) of ≥60.
4. Histologically confirmed diagnosis of cancer with clear evidence of metastasis on imaging. Confirmation of metastasis by biopsy is preferred but not required.
5. Candidates for SBRT delivered as 6Gy x 5 daily fractions to 2 sites of disease. The radiation plan should meet departmental guidelines. Patients can have more than 2 sites of disease. If patient requires RT to other sites of disease this can be done after completion of DLT period.
6. Adequate organ system functions, as outlined below:
7. Absolute neutrophil count (ANC) ≥1.0 x 109/L
8. Platelets ≥75 x 109/L
9. Hemoglobin ≥8 g/dL
10. Total bilirubin ≤1.5 times the ULN
11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the ULN if no liver involvement or ≤5 times the ULN with liver involvement with metastatic disease.
12. Creatinine \<1.5 times ULN concurrent with creatinine clearance \>50 mL/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \>1.5 times ULN.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (5 Sites)

• Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
• Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) — Commack, New York
• Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
• University of Washington (Data Collection AND Data Analysis) — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (800) 525-2225

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumor

• DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer — Basking Ridge, New Jersey
• A Phase 1 Study of BHV-1530 in Advanced Solid Tumors — Newport Beach, California
• A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
• Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors — Hackensack, New Jersey
• A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey

Explore by condition: All Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.